Yvette
Crachi

Business Manager

Fire swinging on Koh Tao, Thailand

I love this photo as it brings back special memories of the wonderful culture and people I encountered whilst honeymooning in Thailand.

photo credit: zoutedrop

New Article - pharmaceutical polymorphs & patent strategy

by Duncan Bucknell

Polymorphs have been a key component of the pharmaceutical patent war for quite some time. Our latest article takes a brief look at the issues and summarises Duncan's presentation on 21 May at the Australian Generic Medicines Association conference in Sydney. Let me know what you think.

Post a Comment | + del.icio.us | + technorati | tweet this | email this

2 Comments

Kate Beattie said

http://vicbar.com.au/c.1.3.aspx?RollNumber=3984

Duncan, re your recent article, as you may be aware, Pumfrey J expressed some thoughts about the validity of a patent for a crystalline form of clarithromycin in Abbott v Ranbaxy and others [2004] EWHC 2723 (decision of Mr. Justice Pumfrey of 19 November 2004). The patent was held to be invalid at an interlocutory stage – but for reasons other than the lack of novelty of a crystalline form patent (which, he suggested, could be novel)

posted on Thursday, May 22, 2008 8:27am

Duncan said

Thanks Kate.

Here's a link to a decision from the Scottish Court of Session which held that a claim to a polymorph of Tibolone with a certain purity was not obvious:

Arrow Generics Ltd v Akzo NB (represented in Scotland by Organon Laboratories Ltd), [2008] CSIH31

Thanks to IPKat for the link.

posted on Sunday, May 25, 2008 5:57pm